RFL
Rafael Holdings·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RFL
Rafael Holdings, Inc.
A company that owns certain commercial real estate assets and investments in clinical and early stage pharmaceutical companies
520 Broad Street, Newark, New Jersey 07102
--
Rafael Holdings, Inc., a biotechnology company incorporated in Delaware, focuses on the development of pharmaceutical products and holds strategic interests in clinical and early-stage biotechnology and medical device companies. The company's lead clinical candidate is Trappsol Cyclo, a therapy being evaluated in pivotal Phase 3 clinical trials for the treatment of Niemann-Pick disease type C1 (NPC1), a rare and fatal genetic disorder that disrupts cholesterol metabolism.
Company Financials
EPS
RFL has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected 0, missing expectations. The chart below visualizes how RFL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RFL has released its 2025 Q4 earnings report, with revenue of 350.00K, reflecting a YoY change of 112.12%, and net profit of -12.05M, showing a YoY change of -148.33%. The Sankey diagram below clearly presents RFL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
